← 所有文章

Dasatinib + Quercetin: Senolytics Hype vs. Human Evidence

Senolytics like dasatinib and quercetin dominate biohacking forums. The problem: every supporting study is in mice. Here's what the evidence actually shows.

What the Papers Actually Say About D+Q and Senolytic Therapy

Dasatinib plus quercetin — D+Q in the biohacking shorthand — has become one of the most hyped longevity protocols on the internet. The pitch is seductive: senescent cells are real, their role in aging is increasingly well-supported, and senolytics are drugs that selectively clear them. Take D+Q intermittently, kill your zombie cells, slow down aging. The concept is scientifically legitimate. The self-administered protocol, based on current human evidence, is not.

Three recent peer-reviewed papers are circulating in senolytic-adjacent communities. Here is what they actually found — and what that means for anyone considering taking dasatinib.

The Three Studies, Translated Honestly

Study 1: D+Q in Diabetic Kidney Disease — EBioMedicine

This study tested dasatinib plus quercetin in mice with diabetic kidney disease. Results were promising within that narrow context: D+Q reduced kidney inflammation, decreased senescent cell abundance, and appeared to restore geroprotective factors in mouse kidney tissue. The paper briefly references a pilot clinical trial in human DKD patients — but that trial's results are not reported here. The mouse experiments are the actual science being presented. The human trial mention is rhetorical scaffolding.

Study 2: Senotoxins and Lipid Membrane Selectivity — Nature Aging

This paper is genuinely interesting mechanistic science, and it is almost completely irrelevant to anything a person can do right now. Researchers found that senescent cells develop a distinct lipid membrane composition — altered ceramide and cholesterol profiles — that makes them selectively vulnerable to a pore-forming toxin derived from sea anemones. The toxin kills senescent cells in culture while largely sparing healthy ones. This is an in vitro study. No animal data. No delivery mechanism for a systemic biological toxin in a living organism. Minimum five years from any clinical application, almost certainly more.

Study 3: Senescence and Retinal Fibrosis — Journal of Translational Medicine

This study examined how senescent endothelial cells drive fibrosis in a mouse model of wet age-related macular degeneration. Senescence-induced endothelial-to-mesenchymal transition (EndMT) was identified as a mechanism contributing to subretinal scarring — a major cause of irreversible vision loss in nAMD. Mechanistically interesting, clinically unexplored, entirely in mice.

Why This Evidence Cannot Support a D+Q Self-Protocol

Animal Data Is Not Human Data

All three studies are either animal experiments or cell culture work. This matters for a simple reason: the research pipeline from "works in mice" to "safe and effective in humans" has an attrition rate exceeding 90%. Senescence biology is particularly difficult to extrapolate between species — mouse immune systems clear senescent cells differently, their inflammatory profiles are distinct, and their compressed lifespans make anti-aging extrapolations to a 40-year human lifespan genuinely heroic assumptions.

When a study reports that D+Q "works" in mice with diabetic kidney disease, the accurate translation is: this compound does something biologically interesting in a model system that partially resembles human disease. That is a useful scientific finding. It is not a treatment recommendation for healthy humans.

Dasatinib Has a Real, Non-Trivial Side Effect Profile

This is the central problem with the D+Q discourse. Quercetin is a plant-derived flavonoid supplement with a low risk profile at the doses discussed. Dasatinib is not a supplement. It is an FDA-approved BCR-ABL tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia and acute lymphoblastic leukemia. Its established side effects include:

Biohacking circles use intermittent, lower doses than oncology protocols. But "lower than chemotherapy dose" has not been rigorously studied for safety in healthy people with no underlying malignancy. Self-administering a cancer drug based on mouse kidney data means assuming risk without the data to calibrate that risk.

The Pilot Trial Reference Is Doing Too Much Work

The EBioMedicine paper cites a pilot clinical trial in human DKD patients as supporting context. Pilot trials are small, typically uncontrolled feasibility studies — they are explicitly not powered to establish efficacy. Citing a pilot trial without reporting its results, in a paper whose actual data is all from mice, is a rhetorical gesture, not a scientific one. Do not let it anchor your risk assessment.

The Senotoxin Finding Is a Hypothesis, Not a Therapy

The lipid membrane selectivity finding in Nature Aging is legitimately exciting basic science. If senescent cells can be reliably targeted via a distinctive lipid composition, that insight could eventually underpin a new class of precision senolytics. The path from "kills senescent cells in a dish" to "safe systemic therapy in humans" involves medicinal chemistry to create a deliverable molecule, animal toxicology, Phase I–III clinical trials, and regulatory approval. We are at step zero of that process.

What Good Evidence Would Actually Look Like

The Mayo Clinic has conducted small human trials of D+Q in specific disease populations — idiopathic pulmonary fibrosis and diabetic kidney disease. Those results are worth monitoring. They are not sufficient to generalize to healthy aging in people without these conditions.

What would constitute genuinely convincing evidence:

That trial does not exist yet.

Verdict

Senolytics are one of the most scientifically credible concepts in aging research. The evidence that senescent cell accumulation drives age-related disease is growing and increasingly convincing. Drugs that selectively clear these cells could eventually matter enormously for human healthspan.

None of that justifies running D+Q on yourself today. The chasm between "credible biological concept" and "proven human intervention" is enormous — and crossing it with a chemotherapy drug, in an unstudied population, at unvalidated doses, for an outcome not yet demonstrated in humans, is precisely how cautionary tales get made.

Watch the Mayo Clinic trials. Follow the next phase of human senolytic research. Don't order dasatinib off the internet.

评论

暂无评论。来发布第一条评论吧！